JPRN-UMIN000007033
Completed
未知
Management of Cardiac Dysfunction Associated With Dystrophinopathy - MAC-D Study
ational Hospital Organization0 sites100 target enrollmentJanuary 7, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- cardiac dysfunction associated with dystrophinopathy
- Sponsor
- ational Hospital Organization
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with the following conditions were excluded: valvular heart disease, hypertrophic obstructive, restrictive, arrhythmogenic right ventricular or advanced inflammatory cardiomyopathy, cardiogenic shock, systolic blood pressure under (80 mm Hg or less at rest, supine), bradycardia (50 orless/min at rest), grade II or III atrioventricular block, life\-threatening arrhythmia, and unstable angina, and resting angina. Patients were also excluded if myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention had occurred within the preceding 3 months and cerebral stroke (transient ischemia, infarction, hemorrhage) had occurred within the preceding 6 months. Severe asthma or other chronic obstructive pulmonary disease and pulmonale. Patients with past history of malignancy or other life threatening diseases diagnosed within 5 years before informed consent. Arteriosclerosis obliterans1 (\>Fontaine degree II) Severe anemia (Hb:6\.0mg or less/dL). Uncontrolled diabetes mellitus. Significant renal impairment defined as a creatinine value 3\.0mg/dL or more. Significant hepatic impairment defined as ALT or AST value 100 or more. Uncontrolled thyroid function disorder. Pregnancy. Allergy or known hypersensitivity to beta blockade. Significant disease, which in the investigator's opinion would exclude the patient from the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 4
Medtronic Cardiac Ablation (Freezes the Heart Tissue to help break electrical signals) Post-Market Study platform which looks at real-world ? product safety and patient clinical outcomes.Health Condition 1: I480- Paroxysmal atrial fibrillationCTRI/2022/02/040484India Medtronic Pvt Ltd
Completed
Not Applicable
Cardiac dysfunction and undiagnosed heart failure in women as a long term effect of the treatment of breast cancer in an unselected primary care settingcardiac dysfunctionheart failure1008220610018865NL-OMON39592niversitair Medisch Centrum Groningen700
Active, not recruiting
Phase 1
Management of the patient with heart failure and diabetes: may insulin be a problem?Heart failure and diabetesMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.1Level: LLTClassification code 10007555Term: Cardiac failure (NOS)System Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-001057-26-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI142
Not yet recruiting
Phase 4
ovel Interventions in Heart Failure with Preserved Ejection Fraction using TadalafilHeart Failure with Preserved Ejection FractionCardiovascular - Other cardiovascular diseasesACTRN12612000684820South Australian Health and Medical Reseasrch Institute20
Not yet recruiting
Phase 4
ovel Interventions in Heart Failure with Preserved Ejection Fraction using ivabradineHeart Failure with Preserved Ejection FractionCardiovascular - Other cardiovascular diseasesACTRN12612000710820South Australian Health and Medical Research Institute20